Literature DB >> 34958818

The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes.

M C Thomas1.   

Abstract

Type 2 diabetes is associated with an increased risk of cardiovascular disease, heart failure, chronic kidney disease, fatty liver disease, eye and foot disease. But equally, these conditions are associated with an increased risk of type 2 diabetes. Rather than being simply considered complications of diabetes, as exists within a 'pure' type 1 diabetes paradigm, both type 2 diabetes and its comorbidities are primarily caused by a failure to efficiently sequester excess energy leading to the accumulation of sick fat (adiposopathy). Type 2 diabetes is a symptom of a chronic disease complex, just as cardiovascular, renal, eye, foot and/or liver disease, are. In addition, each of these conditions feed forward so that dysfunction in one system accelerates dysfunction in another, partly through their shared pathogenesis and partly due dysfunction that follows in their wake. This review will explore the sticky, brittle conglomeration of CArdiac, Renal, Adipo-Metabolic, Eye and Liver disease (hereafter collectively known as CARAMEL disease) that is coincident in most patients with type 2 diabetes and contextualise the recent changes in diabetes guidelines that now specifically focus on identifying and aggressively managing these high-risk individuals with it.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Cardiovascular disease; Diabetic complications; Diabetic eye disease; Diabetic foot disease; Diabetic kidney disease; Metabolic-associated fatty liver disease; Type 2 diabetes

Mesh:

Year:  2021        PMID: 34958818     DOI: 10.1016/j.metabol.2021.154961

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  2 in total

Review 1.  Ten things to know about ten cardiovascular disease risk factors - 2022.

Authors:  Harold E Bays; Anandita Kulkarni; Charles German; Priyanka Satish; Adedapo Iluyomade; Ramzi Dudum; Aarti Thakkar; Mahmoud Al Rifai; Anurag Mehta; Aneesha Thobani; Yousif Al-Saiegh; Adam J Nelson; Samip Sheth; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2022-04-06

2.  Nonalcoholic fatty liver disease in relation to the remission and progression along the glycemic continuum.

Authors:  Zhuojun Xin; Jiaojiao Huang; Qiuyu Cao; Jialu Wang; Ruixin He; Tianzhichao Hou; Yi Ding; Jieli Lu; Min Xu; Tiange Wang; Zhiyun Zhao; Weiqing Wang; Guang Ning; Yufang Bi; Yu Xu; Mian Li
Journal:  J Diabetes       Date:  2022-09       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.